Lasa Supergenerics Limited, a vertically integrated group spanning the entire animal and human healthcare value chain, has announced FY21 profit at Rs. 22.80 crore as compared to a profit of Rs. 3.66 crore in FY20, up by 521% YoY. 

Revenues from operations for FY21 stood at Rs. 202.38 crore as compared to 167.27 crore, up by 21% whereas company registered EBITDA of Rs. 47.28 crore showing y-o-y growth of 56.63%. 

Revenues from operations for the Q4 FY21 ended March 31st stood at Rs. 39.10 crore. The company reported PAT of Rs. 3.82 crore for Q4 FY21. The company’s PAT margin stood at 9.76% Earnings per share (EPS) for the quarter ended Q4 FY21 stood at Rs. 0.93 for the financial year ended 31st March, 2021. 

Commenting on the performance, Dr. Omkar Herlekar, Chairman, Lasa Supergenerics Limited said, “The company under the right leadership and skilled teams turned net positive to post a PAT in last fiscal and now dividend paying company with a robust growth in top via a vis bottom line. 

As I always say let our action speak, results are in line with our commitments of 20% CAGR in topline, what we committed we delivered, we foresee further growth in our numbers if compared to existing added Herlekar. 

Lasa Supergenerics Limited is amongst the leading players in the manufacturing of Veterinary APIs, with a well-established brand known for its high-quality products amongst various customers. The company has its unit with state of art manufacturing facilities located at Mahad and Chiplun, Maharashtra with a total installed capacity of 4,300 MT. The company has over 25% of APIs exported to countries like Australia, Bangladesh, Middle East, China, Turkey, Egypt, Jordan, Korea, Pakistan, etc.